The U.S. Department of Defense wrote a $749,000 check in March 2022. The recipient was a Boulder-based startup with nine employees and a patent for hiding secrets inside DNA [PitchBook, March 2022]. GeneInfoSec’s premise is that the most sensitive data in the world is genetic, and the most secure place to protect it is at the molecular level.
Founded in 2016, the company sells a dual offering. Its core technology is a molecular cryptography platform that synthesizes cryptographic tags attached directly to DNA samples. Its consulting arm provides bioinformatics security audits and staff training [Perplexity Sonar Pro Brief, 2026].
A Cryptographic Wedge in the Test Tube
GeneInfoSec argues the point of failure is earlier than digital systems. Its platform is designed to embed security directly into the physical genetic material. Short, synthesized tags containing cryptographic information are attached to DNA molecules. The data is obfuscated at the sample level, creating "anonymous data sharing" capabilities [SBIR.gov, 2021].
This molecular-first approach is the company’s primary wedge. The company has also developed an interim “pseudomolecular encryption” method applied at the software level post-sequencing [GenomeWeb, August 2021].
The Team Behind the Patent
CEO Sterling Sawaya holds a Ph.D. and is listed as the inventor of molecular cryptography [BioRxiv, 2017]. Co-founder and CTO Aaron Hansen and Co-founder Garrett Schumacher, who also serves as COO, co-authored a foundational paper on genetic information insecurity with Sawaya in 2020 [Frontiers in Bioengineering and Biotechnology, 2020].
| Role | Name | Key Background |
|---|---|---|
| Founder & CEO | Sterling Sawaya, Ph.D. | Inventor of molecular cryptography; author of related academic papers [BioRxiv, 2017]. |
| Co-Founder & CTO | Aaron Hansen | Co-author on genetic security research; former Principal Cybersecurity Expert at GeneInfoSec [LinkedIn, 2026]. |
| Co-Founder & COO | Garrett Schumacher | Co-author on genetic security research; Product Security Director at Velentium Medical [hubXchange, 2026]. |
| Key Personnel | Demetrius King | Co-Founder & Chief Operating Officer [LinkedIn, 2026]. |
Traction and the Government Path
GeneInfoSec’s disclosed financial footprint is government-backed capital. The $749,000 DoD grant in 2022 followed a $46,973 award from the U.S. Air Force in 2021 [SBIR.gov, 2021]. PitchBook notes the 2022 grant was categorized as “Generating Revenue” [PitchBook, March 2022].
| Metric | Value |
|---|---|
| 2021 Air Force Grant | 46.973 K USD |
| 2022 DoD Grant | 749 K USD |
The Commercialization Hurdle
The risks for GeneInfoSec are market adoption and scale. The company operates in a niche defined by two high barriers: the need for wet-lab integration and a customer base that must value genetic data security highly enough to overhaul sample-handling protocols.
- Integration complexity. Adopting molecular cryptography requires changes at the physical sample preparation stage.
- Defined market size. The immediate addressable market appears to be government biosecurity and high-security research labs.
- Funding scale. To date, the company has raised less than $800,000 in disclosed grants.
The Next Twelve Months
The key milestones to watch are a shift from grant funding to venture capital, the signing of a first named commercial customer beyond government contracts, and the publication of a detailed case study using the molecular platform. The hiring of a Senior Software Engineer in January 2025 suggests ongoing product development [LinkedIn, 2026].